Journal Logo

Letters to the Editor

Everolimus and Minimization of Cyclosporine in Renal Transplantation: 24-Month Follow-Up of the EVEREST Study

Ponticelli, Claudio1; Salvadori, Maurizio2; Scolari, Maria Piera3; Citterio, Franco4; Rigotti, Paolo5; Veneziano, Antonella6; Bartezaghi, Marta6 on behalf of EVEREST Study

Author Information
doi: 10.1097/TP.0b013e318216c1db
  • Free

The association of cyclosporine A (CsA) with everolimus can exert synergistic effects on the alloimmune response. CsA inhibits the synthesis of interleukin-2 while everolimus inhibits the response to interleukin-2. Moreover, the interaction with CsA increases the bioavailability of everolimus (1). These data suggest that it is possible to reduce the doses of both drugs when given in combination.

Previously, we reported the 1-year results of a randomized trial in 285 de novo renal transplants, 278 from deceased donors (2). Patients of group A received low-concentration CsA (C2 maintenance levels 350–500 ng/mL) plus everolimus (C0 levels 3–8 ng/mL), while patients of group B received very low-concentration CsA (C2 maintenance levels 150–300 ng/mL) and everolimus at higher target levels (C0 8–12 ng/mL). One-year graft survival rate was better in group B (98% vs. 90%; P=0.007). The mean serum creatinine levels at 1 year were, respectively, 1.51±0.55 mg/dL and 1.55±0.62 mg/dL.

After the 1-year study was completed, 215 patients (110 in group A and 115 in group B) accepted to enter the extension study and to continue the study treatment up to 2 years. At 24 months, the mean everolimus dosages were 1.45±0.6 mg/day in group A (blood levels 6.17±2.1 ng/mL) and 2.24±1.1 mg/day in group B (blood levels 8.15±3.5 ng/mL), and the dosages of CsA were 1.62±0.5 mg/kg/day (C2 levels 407.6±159 ng/mL) and 1.38±0.7 mg/kg/day (C2 blood levels 330.7±159 ng/mL), respectively; the prednisone dosages were 5.14±1.28 mg/day in group A and 4.91±1.10 mg/day in group B.

Four deaths (two in group A and two in group B) occurred within 6 months since transplantation; another patient of group A died after the first year because of myocardial infarction. Fifteen grafts were lost in group A and six in group B (P=0.043). In group A, only one graft was lost after the first year because of recurrent focal glomerular sclerosis. In group B, three failures occurred in the second year; two because of chronic rejection and one because of infection. The 24-month graft survival, including death as a cause of graft failure, was 87.4% in group A and 94.4% in group B (P=0.048).

Acute rejection after the first year occurred in just one patient of group B. The cumulative probability of biopsy-proven rejection at 2 years was 15.0% in group A and 15.7% in group B. The mean levels of serum creatinine at 24 months were 1.45±0.5 mg/dL in group A and 1.52±0.7 mg/dL in group B (P=not significant [NS]). Mean glomerular filtration rate according to Nankivell et al. (3) was 65.8±19.7 mL/min in group A versus 61.8±22.0 mL/min in group B. The slopes of serum creatinine and glomerular filtration rate between 6 months and 2 years were practically flat (data not shown).

At 24 months, systolic blood pressure was 135.6±16.1 mm Hg in group A and 135.8±18.8 mm Hg in group B; diastolic blood pressure was 81.2±9.8 mm Hg in group A versus 81.7±10.4 mm Hg in group B. Most patients were on antihypertensive medication. Mean hemoglobin levels were 13.1±1.6 g/dL in group A and 13.0±1.7 g/dL in group B. Plasma cholesterol levels were 228.0±41 mg/dL in group A and 235.1±54.5 mg/dL in group B (P=NS). Triglycerides levels were 193.3±84.9 mg/dL versus 224.4±120.6 mg/dL (P=NS). 3-hydroxy-3-methyl-glutaryl-Co (HMG-CoA) reductase inhibitors were administered in 83% of patients in both groups. Proteinuria more than 0.2 g/day occurred in 13 patients of group A (9.1%) and in 20 of group B (14.1%).

The overall incidence of infections requiring hospitalization was similar in the two groups (10.5% in group A and 14.5% in group B). Diabetes was diagnosed in 7 (4.9%) patients in group A and in 13 patients (9.2%) in group B (P=NS). One patient (0.7%) in group A and three patients in group B (2.1%) developed nonmelanoma skin cancer. Twelve patients (four in group A and eight in group B) discontinued treatment because of adverse events after the first year (Table 1).

T1-18
TABLE 1:
Adverse events leading to discontinuation of treatment between the first and the second year

From these results, it is possible to conclude that minimal doses of CsA in association with everolimus may offer excellent graft survival and stable renal function at 2 years.

Claudio Ponticelli1

Maurizio Salvadori2

Maria Piera Scolari3

Franco Citterio4

Paolo Rigotti5

Antonella Veneziano6

Marta Bartezaghi6

on behalf of EVEREST Study

1Division of Nephrology

Humanitas Scientific Institute

Rozzano (Milano), Italy

2Division of Nephrology

Careggi Hospital

Firenze, Italy

3Renal Transplant Unit

S. Orsola Malpighi University Hospital

Bologna, Italy

4Department of Surgery

Catholic University Hospital

Roma, Italy

5Surgery Division

Policlinic University Hospital

Padova, Italy

6Medical Department

Novartis Italy

Origgio (Varese), Italy

REFERENCES

1. Kovarik JM, Dantal J, Civati G, et al. Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients. Am J Transplant 2003; 3: 1576.
2. Salvadori M, Scolari MP, Bertoni E, et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: A multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
3. Nankivell BJ, Chapman JR, Allen RD. Predicting glomerular filtration rate after simultaneous pancreas and kidney transplantation. Clin Transplant 1995; 9: 129.
© 2011 Lippincott Williams & Wilkins, Inc.